EMEA recommends the suspension of the marketing authorisation of Ionsys (fentanyl hydrochloride)

The European Medicines Agency (EMEA)The European Medicines Agency (EMEA) has recommended the suspension of the marketing authorisation of Ionsys (fentanyl hydrochloride), from Janssen-Cilag International NV, because of a defect with the delivery system of the medicine that could lead to patients being overdosed.

Ionsys is a system for the transdermal delivery of fentanyl, an opioid analgesic. It has been authorised in the European Union (EU) since January 2006 and is indicated for the management in hospital of acute moderate to severe post-operative pain. The system is activated on demand by the patient in response to pain.

The EMEA's Committee for Medicinal Products for Human Use (CHMP) was informed by the marketing authorisation holder, Janssen-Cilag International NV, that it had detected corrosion of a component of the system in one batch of Ionsys. This could trigger the self-activation of the system, which could lead to fentanyl overdose. This could subsequently cause respiratory depression, a life-threatening complication.

There have been no reports of serious adverse events associated with the malfunction of the device, in particular no reports related to self-activation of the system, or of overdose as a result. However, the marketing authorisation holder recalled all systems from the EU in September 2008 as a precautionary measure. As a consequence, Ionsys is unavailable and patients have been switched to alternative treatments.

The marketing authorisation holder has started a root-cause analysis of the defect, but has been unable to identify the cause of the defect. The company has also been unable to detect the defect with the quality control systems currently in place in the manufacturing and testing sites. In addition, the company's quality systems have been unable to resolve the problems with Ionsys and to prevent this quality defect occurring.

Because of this and the risks of fentanyl overdose, the CHMP has concluded that the benefits of Ionsys no longer outweigh its risks and has recommended the suspension of the marketing authorisation until the marketing authorisation holder can robustly demonstrate the quality of the product.

The CHMP opinion will now be sent to the European Commission for the adoption of a decision, applicable in all EU Member States.

More information on Ionsys is available in the European Public Assessment Report on the Agency's website at: http://www.emea.europa.eu/humandocs/Humans/EPAR/ionsys/ionsys.htm

For further information, please visit:
http://www.emea.europa.eu

Most Popular Now

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Adequate levels of vitamin D reduces complications…

Hospitalized COVID-19 patients who were vitamin D sufficient, with a blood level of 25-hydroxyvitamin D of at least 30 ng/mL (a measure of vitamin D status), had a signif...

Gilead Sciences signs joint procurement agreement …

Gilead Sciences (Nasdaq: GILD) and the European Commission signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir)...

Protective antibodies persist for months in surviv…

People who survive serious COVID-19 infections have long-lasting immune responses against the virus, according to a new study led by researchers at Massachusetts General ...

Potential COVID-19 vaccines not affected by domina…

Vaccines currently being developed for COVID-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologis...

Regeneron's REGN-COV2 antibody cocktail reduced vi…

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cockta...

Popular COVID-19 conspiracies linked to vaccine 'h…

A new study of beliefs and attitudes toward COVID-19 in five different countries - UK, US, Ireland, Mexico and Spain - has identified how much traction some prominent con...